Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
During the past 12 months, Australian Clinical Labs's average Book Value per Share Growth Rate was -8.30% per year.
During the past 3 years, the average Book Value per Share Growth Rate was -2.10% per year.
During the past 5 years, the average Book Value per Share Growth Rate was 7.70% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.
During the past 7 years, the highest 3-Year average Book Value per Share Growth Rate of Australian Clinical Labs was 54.20% per year. The lowest was -8.80% per year. And the median was 13.65% per year.
Australian Clinical Labs (ASX:ACL) 3-Year Book Growth Rate Explanation
Book Value per Share is the ratio of equity available to common shareholders divided by the shares outstanding. Book value per share effectively indicates a firm's net asset value on a per-share basis. It can be used by investors to gauge whether a stock price is undervalued by comparing it to the firm's market value per share. Theoretically, it is what the shareholders will receive if the company is liquidated.
Australian Clinical Labs 3-Year Book Growth Rate Related Terms
ASX:ACL vs TMO, DHR, NTRA: 3-Year Book Growth Rate Comparison
For the Diagnostics & Research subindustry, Australian Clinical Labs's 3-Year Book Growth Rate, along with its competitors' market caps and 3-Year Book Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Australian Clinical Labs 3-Year Book Growth Rate vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Australian Clinical Labs's 3-Year Book Growth Rate distribution charts can be found below:
* The bar in red indicates where Australian Clinical Labs's 3-Year Book Growth Rate falls into.
Australian Clinical Labs 3-Year Book Growth Rate Calculation
This is the 3-year average growth rate of Book Value per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.
What does a 3-Year Book Growth Rate of -2.10% mean?
Australian Clinical Labs (ASX:ACL) has a 3-Year Book Growth Rate of -2.10% as of Jun. 2026. 3-Year Book Growth Rate is the 3-year average growth rate of Book Value per Share. View historical data for Australian Clinical Labs and its competitors. According to the industry distribution chart, Australian Clinical Labs ranks #93 out of 191 companies in the Medical Diagnostics & Research industry, placing it in the top 48.7%.
Is Australian Clinical Labs' 3-Year Book Growth Rate too high?
Australian Clinical Labs' current 3-Year Book Growth Rate is -2.10%. Based on the distribution chart, Australian Clinical Labs ranks #93 out of 191 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Australian Clinical Labs has a GF Score™ of 76/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Australian Clinical Labs' 3-Year Book Growth Rate compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Australian Clinical Labs ranks #93 out of 191 companies for 3-Year Book Growth Rate. This puts Australian Clinical Labs in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year Book Growth Rate for a Medical Diagnostics & Research company?
A good 3-Year Book Growth Rate depends on the Medical Diagnostics & Research industry context. However, 3-Year Book Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year Book Growth Rate mean?
A high 3-Year Book Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year Book Growth Rate is the 3-year average growth rate of Book Value per Share. View historical data for Australian Clinical Labs and its competitors. Australian Clinical Labs's current 3-Year Book Growth Rate is -2.10%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Australian Clinical Labs stock overvalued right now?
Based on GuruFocus' analysis, Australian Clinical Labs (ASX:ACL) is currently considered Fairly Valued. The stock's GF Value™ is A$2.95, compared to a current price of A$2.80 — trading 5.1% below its estimated fair value. The current 3-Year Book Growth Rate is -2.10%. Australian Clinical Labs' overall GF Score™ is 76/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year Book Growth Rate calculated?
3-Year Book Growth Rate is calculated from a company's financial statements. For Australian Clinical Labs (ASX:ACL), the current 3-Year Book Growth Rate is -2.10% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Australian Clinical Labs (ASX:ACL) Overvalued in 2026?
Based on GuruFocus' analysis, Australian Clinical Labs stock appears to be undervalued.
The current stock price of A$2.80 is trading 5.1% below its estimated GF Value™ of A$2.95.
GuruFocus considers Australian Clinical Labs to be Fairly Valued.
Key valuation signals for ASX:ACL:
3-Year Book Growth Rate: -2.10%
GF Value™: A$2.95 vs. price of A$2.80 (5.1% below fair value)
No single metric tells the full story. See the ASX:ACL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Australian Clinical Labs is Australia's third-largest private pathology provider. ACL earns almost its entire group revenue from pathology services in Australia, which are mostly earned via the publicly funded health Medicare system. ACL is well established in the states of Western Australia, South Australia, Victoria, and the Northern Territory.
76GF Score
Get the complete analysis for ASX:ACL
3-Year Book Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:ACL has been successfully added to your 
